Nektar Therapeutics (NASDAQ: NKTR) reported Q3 EPS of ($0.19), $0.01 better than the analyst estimate of ($0.20). Revenue for the quarter came in at $24.1 million versus the consensus estimate of $21.26 million.

For earnings history and earnings-related data on Nektar Therapeutics (NKTR) click here.